We are live on ! Find out more
IMMX icon

Immix Biopharma
IMMX

67 hedge funds and large institutions have $127M invested in Immix Biopharma in 2025 Q4 according to their latest regulatory filings, with 41 funds opening new positions, 17 increasing their positions, 6 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

2,105% more capital invested

Capital invested by funds: $5.78M → $127M (+$122M)

720% more first-time investments, than exits

New positions opened: 41 | Existing positions closed: 5

183% more repeat investments, than reductions

Existing positions increased: 17 | Existing positions reduced: 6

116% more funds holding

Funds holding: 31 → 67 (+36)

63.02% more ownership

Funds ownership: 9.59% → 72.62% (+63%)

48% less call options, than puts

Call options by funds: $225K | Put options by funds: $436K

Holders
67
Holders Change
+36
Holders Change %
+116.13%
% of All Funds
0.81%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
41
Increased
17
Reduced
6
Closed
5
Calls
$225K
Puts
$436K
Net Calls
-$211K
Net Calls Change
-$211K

Top Buyers

Rank Fund Capital Flow
1
Janus Henderson Group
Janus Henderson Group
United Kingdom
+$16.1M
2
SVCM
Saturn V Capital Management
Texas
+$12.3M
3
EAM
Eventide Asset Management
Massachusetts
+$10.5M
4
Marshall Wace
Marshall Wace
United Kingdom
+$7.92M
5
Millennium Management
Millennium Management
New York
+$6.83M

Top Sellers

Rank Fund Capital Flow
1
IW
Imprint Wealth
South Carolina
-$195K
2
Citadel Advisors
Citadel Advisors
Florida
-$59.5K
3
TW
TritonPoint Wealth
Maryland
-$51.3K
4
SS
SBI Securities
Japan
-$30.9K
5
Focus Partners Wealth
Focus Partners Wealth
Massachusetts
-$24.9K
Name Holding Trade Value Shares
Change 		Change in
Stake
Northern Trust
26
Northern Trust
Illinois
$526K +$46.7K +11,357 +13%
Bank of New York Mellon
27
Bank of New York Mellon
New York
$516K +$406K +98,732 New
LP
28
Longaeva Partners
Illinois
$513K +$403K +98,040 New
State Street
29
State Street
Massachusetts
$509K -$6.58K -1,600 -2%
Citadel Advisors
30
Citadel Advisors
Florida
$394K -$59.5K -14,460 -16%
OAC
31
OMERS Administration Corp
Ontario, Canada
$391K +$307K +74,700 New
VF
32
Virtu Financial
New York
$386K +$304K +73,791 New
SEI Investments
33
SEI Investments
Pennsylvania
$385K +$303K +73,570 New
UCFA
34
United Capital Financial Advisors
Texas
$370K – – –
TAM
35
Tocqueville Asset Management
New York
$359K +$116K +28,300 +70%
UBS Group
36
UBS Group
Switzerland
$306K +$233K +56,659 +2,921%
ACM
37
ADAR1 Capital Management
Texas
$262K +$206K +50,000 New
Qube Research & Technologies (QRT)
38
Qube Research & Technologies (QRT)
United Kingdom
$261K +$205K +49,814 New
XT
39
XTX Topco
Cayman Islands
$243K +$46.3K +11,241 +32%
CIBC Private Wealth Group
40
CIBC Private Wealth Group
Georgia
$209K +$123K +30,000 +300%
VCIM
41
Velan Capital Investment Management
Georgia
$183K – – –
Barclays
42
Barclays
United Kingdom
$183K +$144K +35,000 New
JF
43
Jump Financial
Illinois
$177K +$139K +33,800 New
Hudson Bay Capital Management
44
Hudson Bay Capital Management
Connecticut
$176K +$138K +33,649 New
PAP
45
Persistent Asset Partners
Hong Kong
$166K +$131K +31,755 New
PAG
46
Private Advisor Group
New Jersey
$166K +$2.06K +500 +2%
CIA
47
Concurrent Investment Advisors
Florida
$143K +$113K +27,431 New
TP
48
TritonPoint Partners
Maryland
$128K +$101K +24,526 New
QC
49
Quadrature Capital
United Kingdom
$116K +$91K +22,120 New
Squarepoint
50
Squarepoint
New York
$112K +$88.5K +21,500 New
1
2
3

IMMX Hedge Fund Activity: Q4 2025 in Review

67 of the 8,228 institutional investors tracked by Wall St. Rank reported a position in Immix Biopharma (IMMX) for Q4 2025, worth a combined $127M — up 2,105% from $5.78M a quarter earlier.

Buyers outnumbered sellers: 41 funds opened new IMMX positions and 5 closed out — a net gain of 36 holders — while 17 added to existing stakes and 6 trimmed.

The largest buyer was Janus Henderson Group, opening a new position worth an estimated $16.1M. The largest seller was Imprint Wealth, cutting an estimated $195K.

  • 67 institutional investors held Immix Biopharma (IMMX) as of Q4 2025, up from 31 in Q3 2025.
  • Funds reported $127M of Immix Biopharma stock for Q4 2025, up 2,105% quarter-over-quarter.
  • 41 funds opened new Immix Biopharma positions in Q4 2025 and 5 closed out, a net change of +36 holders.
  • The largest Immix Biopharma buyer in Q4 2025 was Janus Henderson Group, an estimated $16.1M added.
  • The largest Immix Biopharma seller in Q4 2025 was Imprint Wealth, an estimated $195K sold.

Based on aggregated 13F filings for Q4 2025.